MetLife Investment Advisors LLC Sells 64 Shares of ABIOMED, Inc. (NASDAQ:ABMD)

MetLife Investment Advisors LLC cut its position in shares of ABIOMED, Inc. (NASDAQ:ABMD) by 0.5% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 12,814 shares of the medical equipment provider’s stock after selling 64 shares during the quarter. MetLife Investment Advisors LLC’s holdings in ABIOMED were worth $3,660,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of ABMD. Nordea Investment Management AB raised its holdings in shares of ABIOMED by 23.1% during the 1st quarter. Nordea Investment Management AB now owns 2,443 shares of the medical equipment provider’s stock worth $696,000 after buying an additional 459 shares in the last quarter. Cerebellum GP LLC raised its holdings in shares of ABIOMED by 43.4% during the 1st quarter. Cerebellum GP LLC now owns 1,153 shares of the medical equipment provider’s stock worth $329,000 after buying an additional 349 shares in the last quarter. Marshall Wace North America L.P. raised its holdings in shares of ABIOMED by 6.2% during the 1st quarter. Marshall Wace North America L.P. now owns 190,510 shares of the medical equipment provider’s stock worth $54,408,000 after buying an additional 11,194 shares in the last quarter. Marshall Wace LLP grew its position in ABIOMED by 36.6% during the 1st quarter. Marshall Wace LLP now owns 4,549 shares of the medical equipment provider’s stock worth $1,299,000 after acquiring an additional 1,219 shares during the last quarter. Finally, Meridian Wealth Management LLC bought a new stake in ABIOMED during the 1st quarter worth $40,000. Institutional investors and hedge funds own 87.09% of the company’s stock.

In other ABIOMED news, Director Martin P. Sutter sold 4,664 shares of the stock in a transaction on Wednesday, May 8th. The stock was sold at an average price of $259.97, for a total transaction of $1,212,500.08. Following the completion of the transaction, the director now directly owns 192,550 shares of the company’s stock, valued at $50,057,223.50. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 3.40% of the company’s stock.

ABMD has been the topic of a number of research reports. BidaskClub upgraded ZIOPHARM Oncology from a “buy” rating to a “strong-buy” rating in a research report on Monday, June 17th. ValuEngine lowered Whiting USA Trust II from a “hold” rating to a “sell” rating in a research report on Tuesday, May 7th. BTIG Research reiterated a “buy” rating on shares of ABIOMED in a research report on Tuesday, May 7th. SunTrust Banks upped their price target on Paylocity to $108.00 and gave the company a “positive” rating in a research report on Friday, May 3rd. Finally, Zacks Investment Research lowered Haynes International from a “hold” rating to a “sell” rating in a research report on Wednesday, May 8th. Three research analysts have rated the stock with a sell rating and three have assigned a buy rating to the company’s stock. ABIOMED presently has an average rating of “Hold” and a consensus price target of $378.00.

Shares of ABIOMED stock traded down $3.40 on Friday, hitting $262.69. The company had a trading volume of 400,123 shares, compared to its average volume of 423,173. The firm has a market capitalization of $11.90 billion, a PE ratio of 72.97, a price-to-earnings-growth ratio of 2.08 and a beta of 0.32. ABIOMED, Inc. has a 1 year low of $228.00 and a 1 year high of $459.75. The stock’s 50 day simple moving average is $261.43.

ABIOMED (NASDAQ:ABMD) last released its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.07 by $0.53. The company had revenue of $207.08 million during the quarter, compared to analyst estimates of $218.88 million. ABIOMED had a return on equity of 20.32% and a net margin of 33.66%. ABIOMED’s quarterly revenue was up 18.7% on a year-over-year basis. During the same period in the prior year, the company posted $0.80 earnings per share. As a group, analysts predict that ABIOMED, Inc. will post 4.5 EPS for the current fiscal year.

ABIOMED Profile

ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.

Recommended Story: What is a balanced fund?

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.